SCHEMBL26533932

SCHEMBL26533932

CCOC(=O)CCc1ccc(N(c2ccc(CCC(C)=O)cc2)c2ccc(C)c(C)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.54
CYP4A11 Q02928 2/20 0.54
CYP4Z1 Q86W10 3/20 0.47
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
P2RY12 Q9H244 1/20 0.41
CYP4F11 Q9HBI6 1/20 0.40
CYP4F12 Q9HCS2 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HRH3 Q9Y5N1 1/20 0.39
HTT P42858 1/20 0.39
ALOX5 P09917 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26534594 0.95 CYP4F2 (0.59) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A
SCHEMBL5531196 0.91 CYP4F2 (0.55) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A
SCHEMBL26533923 0.89 CYP4F2 (0.42) CYP4F2CYP4A11CYP4Z1ALDH1A1LMNA
SCHEMBL14018801 0.87 CYP4F2 (0.40) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A
SCHEMBL8055023 0.85 CYP4F2 (0.47) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A
SCHEMBL14732613 0.84 CYP4F2 (0.44) CYP4F2CYP4A11CYP4Z1ALDH1A1HRH3
SCHEMBL26534435 0.84 CYP4F2 (0.46) CYP4F2CYP4A11CYP4Z1ALDH1A1LMNA
SCHEMBL14733311 0.83 CYP4F2 (0.43) CYP4F2CYP4A11CYP4Z1ALDH1A1HRH3
SCHEMBL2602507 0.82 CYP4F2 (0.45) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A
SCHEMBL2602468 0.82 CYP4F2 (0.45) CYP4F2CYP4A11CYP4Z1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230136697-A1 METHODS FOR PRODUCING ARYLAMINE COMPOUND AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER CANON KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136697-A1 METHODS FOR PRODUCING ARYLAMINE COMPOUND AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER TYR, PAH, AHR CYP4F2 126/4885CYP4A11 172/4885CYP4Z1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.